Home Artio Medical

Artio Medical

Flow Forward Medical Acquired by Artio Medical

This stock-for-stock merger transaction in which Flow Forward Medical merged with and into Artio was approved by the Board of Directors and stockholders of both companies. The transaction closed on June 8, 2020.  

Endura Embolization Device Interim Study Highlighted at Neurovascular Conference

The interim data demonstrated that use of the Endura™ Embolization System in bifurcation aneurysms can result in greater aneurysm occlusion and lower coil prolapse into parent arteries when compared to commercially available coil-only treatments.

Metactive Medical Announces Name Change to Artio Medical

Artio Medical was founded in 2014 as a small R&D group focused on developing metal implants for vascular embolization.

MetactiveMedical Raises $1.2 Million of Additional Capital and Awarded $1.5 Million Grant from the National Institutes of Health

This new investment capital and grant funding will be used to continue the development of our novel platform of embolic products, which we believe will provide physicians with devices that are exceptionally deliverable, can be placed with a high level of precision, are resistant to migration, and provide immediate, complete, and lasting occlusion,” stated F. Nicholas Franano, MD, President and CEO of Metactive.

Metactive Medical Announces Issuance of Patents on Blockstent and Ballstent Embolization Devices

Metactive also announced the closing of $1.5 million of additional Series A financing, co-led by Mid-America Angels, with the participation of a family office and additional individual investors. Metactive previously raised $7.5 million in Series A funding, bringing the total funding raised to $9 million.